Actively Recruiting
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Led by Celltrion · Updated on 2025-08-15
486
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
CONDITIONS
Official Title
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Documented multiple myeloma according to IMWG criteria
- Documented relapsed or refractory disease
- Achieved partial response or better to at least one prior treatment regimen
- Disease progression as defined by IMWG criteria after the last therapy
You will not qualify if you...
- Previous use of daratumumab or any drug targeting CD38
- Disease refractory or intolerant to lenalidomide
- Unable to comply with the study protocol or any condition that may affect safety or study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taipei Veterans General Hospital
Taipei, Beitou District, Taiwan, 11217
Actively Recruiting
Research Team
J
JoonSoo Ha
CONTACT
N
NaRae Ryu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here